The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"

Clin Obstet Gynecol. 2012 Mar;55(1):24-35. doi: 10.1097/GRF.0b013e31824b1725.

Abstract

A novel origin for pelvic serous cancer (ovarian cancer) has been proposed in the distal oviduct. This has important implications, including both early detection in high-risk women and wisdom of relying on serological tests to detect a disease that begins so close to the peritoneal surfaces. With the recent discovery of premalignant disturbances in gene function in the tubal mucosa, the concept of targeted prevention is emerging whereby the interruption of a portion of the carcinogenic pathway will prevent cancer. This alternative to detect early malignancy is a new paradigm in the quest to prevent this deadly disease.

Publication types

  • Review

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Carcinoma in Situ / genetics
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / prevention & control*
  • Cell Transformation, Neoplastic / metabolism
  • Cystadenocarcinoma, Serous / genetics
  • Cystadenocarcinoma, Serous / pathology
  • Cystadenocarcinoma, Serous / prevention & control*
  • Early Diagnosis
  • Fallopian Tube Neoplasms / genetics
  • Fallopian Tube Neoplasms / pathology
  • Fallopian Tube Neoplasms / prevention & control
  • Fallopian Tubes / pathology
  • Fallopian Tubes / surgery
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genetic Predisposition to Disease
  • Humans
  • Mutation
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / prevention & control*
  • Ovariectomy
  • Tumor Suppressor Protein p53 / genetics

Substances

  • BRCA1 Protein
  • BRCA2 Protein
  • Tumor Suppressor Protein p53